1. Home
  2. PRTA vs LAB Comparison

PRTA vs LAB Comparison

Compare PRTA & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

HOLD

Current Price

$10.82

Market Cap

539.9M

Sector

Health Care

ML Signal

HOLD

Logo Standard BioTools Inc.

LAB

Standard BioTools Inc.

HOLD

Current Price

$0.98

Market Cap

354.1M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRTA
LAB
Founded
2012
1999
Country
Ireland
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Laboratory Analytical Instruments
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
539.9M
354.1M
IPO Year
2013
2008

Fundamental Metrics

Financial Performance
Metric
PRTA
LAB
Price
$10.82
$0.98
Analyst Decision
Buy
Hold
Analyst Count
9
1
Target Price
$19.00
$1.35
AVG Volume (30 Days)
453.1K
2.4M
Earning Date
05-07-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
61.54
EPS
N/A
N/A
Revenue
$814,000.00
$101,937,000.00
Revenue This Year
$1,111.38
N/A
Revenue Next Year
N/A
$2.63
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.32
$0.87
52 Week High
$11.69
$1.72

Technical Indicators

Market Signals
Indicator
PRTA
LAB
Relative Strength Index (RSI) 67.15 52.37
Support Level $9.69 $0.92
Resistance Level $10.90 $1.01
Average True Range (ATR) 0.40 0.05
MACD 0.10 0.01
Stochastic Oscillator 96.87 88.90

Price Performance

Historical Comparison
PRTA
LAB

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

About LAB Standard BioTools Inc.

Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.

Share on Social Networks: